Xtant Medical Raises FY23 Revenue Guidance To $75M-$77M, Vs. Consensus Of $75M (Prior Guidance: $73M-$75M)
Portfolio Pulse from Benzinga Newsdesk
Xtant Medical Holdings, Inc. (AMEX:XTNT) has raised its FY23 revenue guidance to $75M-$77M, compared to the consensus of $75M and prior guidance of $73M-$75M. This represents an annual revenue growth of approximately 29% to 33% compared to full year 2022 revenue. The revised guidance excludes any potential contributions from the Surgalign transaction.
August 01, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xtant Medical's raised FY23 revenue guidance could potentially lead to a positive impact on its stock price. However, the exclusion of potential contributions from the Surgalign transaction might be a point of concern for investors.
The raised revenue guidance indicates a strong financial performance by Xtant Medical, which could attract investors and drive up the stock price. However, the exclusion of potential contributions from the Surgalign transaction might indicate uncertainty around this deal, which could concern some investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100